QGEN · Qiagen N.V.
$42.50
+0.88% last session
End-of-day data · close of 2026-09-11
Market cap
$9B
Enterprise value
$10B
Trailing P/E
21.6
Forward P/E
16.1
Dividend yield
1.0%
Beta
0.63
Avg volume
3M
Employees
6K
Daily Change %
0.88%
5 Days Change
-2.23%
10 Days Change
-1.82%
30 Days Change
-0.35%
60 Days Change
2.38%
Month to Day Change
-2.05%
Year to Day Change
-4.64%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — QGEN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
UBS
Neutral$47.00
+11.6% vs priceCitigroup
Neutral$45.00
+6.8% vs priceBarclays
Equal-Weight$40.00
-5.1% vs priceJP Morgan
Overweight$50.00
+18.7% vs priceMorgan Stanley
Overweight$42.00
-0.3% vs priceDeutsche Bank
Buy$54.00
+28.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | UBS | Maintains | Neutral | $52.00 → $47.00 |
| 2026-08-10 | Citigroup | Maintains | Neutral | $38.00 → $45.00 |
| 2026-08-07 | Barclays | Maintains | Equal-Weight | $38.00 → $40.00 |
| 2026-08-07 | JP Morgan | Maintains | Overweight | $45.00 → $50.00 |
| 2026-06-23 | Morgan Stanley | Upgrade | Equal-Weight → Overweight | $40.00 → $42.00 |
| 2026-05-18 | Stifel | Maintains | Hold | $50.00 → $36.00 |
| 2026-05-07 | TD Cowen | Maintains | Hold | $46.00 → $40.00 |
| 2026-04-29 | JP Morgan | Maintains | Overweight | $60.00 → $45.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.9% above the 50-day MA ($42.12).
- Price vs 200-day MA: Trading 0.3% above the 200-day MA ($42.38).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.26) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($32.34) and high ($55.16).
QGEN Price Chart
Loading chart for QGEN…
Fundamentals
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
More in Diagnostics & Research
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.